Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced two presentations during the ACMG Annual Clinical Genetics Meeting,...
-
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year with First Participant Dosed and Others in Screening - - Initial Clinical Data from Gene Therapy Trial for Hunter...
-
BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical...
-
BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive...
-
Preclinical Studies Demonstrated a Targeted Immunosuppression Approach Led to Reduced Immune Response to AAVHSC Administration and Improved Gene Expression In Vivo Gene Therapy Candidate HMI-204 for...
-
Strong Cash Position with Runway into Fourth Quarter 2024 Non-Clinical Data on Immunosuppression Regimen Supportive of Clinical Programs Preclinical Data from HMI-103 Gene Editing Program Utilizing...
-
- On Track for Updates on pheEDIT and juMPStart Programs by Year-End - - Strong Financial Position with Cash Runway into Fourth Quarter 2024 - - Promoted Albert Seymour, Ph.D., to Chief Executive...
-
- Additional Presentation Focused on Use of Single-Molecule, Modified Base Sequencing to Support Vector Design - BEDFORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq:...
-
BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences. ...
-
Arthur Tzianabos, Ph.D., Named Chairperson of the Board of Directors BEDFORD, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company,...